Schonfeld Strategic Advisors’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio STSA Stock Details STSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-11,300	Closed	-$68K	–	3210
2022 Q3	$68K	Sell	11,300 -100	-0.9%	-$567	﹤0.01%	2606
2022 Q2	$47K	Sell	11,400 -10,100	-47%	-$35.6K	﹤0.01%	2230
2022 Q1	$81K	Buy	21,500 +7,500	+54%	+$33.8K	﹤0.01%	2274
2021 Q4	$63K	Sell	14,000 -200	-1%	-$1.01K	﹤0.01%	1934
2021 Q3	$67K	Buy	+14,200	New	+$75.2K	﹤0.01%	1974
2021 Q2	–	Sell	-14,400	Closed	-$86K	–	2444
2021 Q1	$86K	Sell	14,400 -1,200	-8%	-$7.27K	﹤0.01%	1682
2020 Q4	$72K	Buy	+15,600	New	+$67.2K	﹤0.01%	1478
2020 Q3	–	Sell	-11,000	Closed	-$317K	–	1755
2020 Q2	$317K	Buy	+11,000	New	+$255K	0.01%	973

Other funds holding STSA

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NFGH

Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Schonfeld Strategic Advisors's STSA Position: Q4 2022 in Review

Schonfeld Strategic Advisors sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q4 2022, closing a stake of 11,300 shares — an estimated $68K sold.

Schonfeld Strategic Advisors first reported a position in STSA in Q2 2020 and held it in 8 quarters. The position peaked at $317K in Q2 2020. 33 funds tracked by Wall St. Rank hold STSA as of Q4 2022.

Schonfeld Strategic Advisors reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Schonfeld Strategic Advisors sold 11,300 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $68K.
Schonfeld Strategic Advisors first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 8 quarters.
Schonfeld Strategic Advisors's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $317K in Q2 2020.
33 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.